Sagar Trivedi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sagar Trivedi has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Veena Belgamwar
Rashtrasant Tukadoji Maharaj Nagpur University
8 shared publicationsRishabh Agade
7 shared publicationsKamlesh Wadher
4 shared publicationsAditi Sonone
3 shared publications- Kamlesh Wadher
Department of Pharmaceutics, Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur, Maharashtra, India 441002
3 shared publications Mansi Thakur
3 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by KEAI Publishing in Transformative Medical Materials
- Vol. 1 (2)
UV-visible spectroscopic based quantitative estimation of intranasal dasatinib-encapsulated polymeric nanoparticles in simulated nasal fluid
- 1 September 2026
- Published by KEAI Publishing in Transformative Medical Materials
- Vol. 1 (2)
Open AccessUV-visible spectroscopic based quantitative estimation of intranasal dasatinib-encapsulated polymeric nanoparticles in simulated nasal fluid
- 11 August 2026
- Published by Taylor & Francis in Nanomedicine
- Vol. 21 (16) , 2335-2354
LPR-1-Mediated targeted intranasal delivery of lentinan-loaded polymeric nanocarriers for GBM therapy via modulation of apoptotic signalling
1. Glioblastoma (GBM) is the most aggressive and deadly primary brain cancer, known for its rapid growth, extensive infiltration, and highly adaptable microenvironment. Despite advances in neurosur...
- 11 August 2026
- Published by Taylor & Francis in Nanomedicine
- Vol. 21 (16) , 2335-2354
LPR-1-Mediated targeted intranasal delivery of lentinan-loaded polymeric nanocarriers for GBM therapy via modulation of apoptotic signalling
1. Glioblastoma (GBM) is the most aggressive and deadly primary brain cancer, known for its rapid growth, extensive infiltration, and highly adaptable microenvironment. Despite advances in neurosur...
- Open Access
- 1 June 2026
- Published by KEAI Publishing in Precision Medication
- Vol. 3 (2)
Cell-penetrating peptides as a gateway for nanocarrier-mediated glioblastoma therapy
- 1 June 2026
- Published by KEAI Publishing in Precision Medication
- Vol. 3 (2)
Open AccessCell-penetrating peptides as a gateway for nanocarrier-mediated glioblastoma therapy
- Open Access
- 2 April 2026
- Published by Springer Nature in Discover Green Chemistry
- Vol. 1 (1)
Green chemistry integrated quality by design based RP-HPLC method for analysis of Itraconazole in pharmaceutical formulations
- 2 April 2026
- Published by Springer Nature in Discover Green Chemistry
- Vol. 1 (1)
Open AccessGreen chemistry integrated quality by design based RP-HPLC method for analysis of Itraconazole in pharmaceutical formulations
- Open Access
- 1 September 2025
- Published by KEAI Publishing in Precision Medication
- Vol. 2 (3)
Advances and challenges in personalized diagnosis and therapies for the management of recurrent glioblastoma
- 1 September 2025
- Published by KEAI Publishing in Precision Medication
- Vol. 2 (3)
Open AccessAdvances and challenges in personalized diagnosis and therapies for the management of recurrent glioblastoma
- Open Access
- 1 August 2025
- Published by Elsevier in Next Nanotechnology
- Vol. 8
Advances in bridging computational and clinical outcomes in brain tumour therapy by leveraging artificial intelligence and machine learning
- 1 August 2025
- Published by Elsevier in Next Nanotechnology
- Vol. 8
Open AccessAdvances in bridging computational and clinical outcomes in brain tumour therapy by leveraging artificial intelligence and machine learning
- 20 July 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (8) , 5075-5093
Engineering of Dual-Functionalized Intranasal Nanovesicles Embedded with Thymoquinone for Targeted Modulation of the PI3K/AKT Pathway in Glioblastoma Therapy
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor, known for its invasiveness, therapy resistance, and the challenge posed by the blood-brain barrier (BBB). This study presents a novel, dual-functionalized nanovesicular system for intranasal delivery of thymoquinone (TH), encapsulated in PEGylated chitosan-coated NVs and conjugated with lactoferrin (Lf). This formulation (TH-Lf-PEG-CS-NVs) was optimized using a central composite design and exhibited high entrapment efficiency (96.28 ± 0.65%), a particle size of 129.82 ± 0.53 nm, and coating efficiency of 91.72 ± 0.22%. In vitro and ex vivo studies demonstrated superior cellular uptake (84.01 ± 3.78%) and a ∼3.16-fold increase in permeability (Papp: 0.57 ± 0.072 μg/cm2/min) compared to free TH. Mechanistic assays confirmed modulation of the PI3K/AKT pathway, with reduced Bcl-2 (56.91 ± 2.98%), COX-2 (31.22 ± 2.19%), and increased caspase-3 (75.9 ± 3.01%) expression. In vivo pharmacokinetics revealed a peak cerebrospinal fluid concentration (Cmax) of 51.72 ± 1.22 μg/mL at 24 h and sustained release for 36 h. Histopathological evaluations affirmed safety and biocompatibility. This multifunctional nanocarrier facilitates targeted delivery, effective BBB penetration, and prolonged cerebral retention, offering a noninvasive, efficient strategy for GBM treatment. The findings support its potential as a translational therapeutic platform for central nervous system malignancies.
- 20 July 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (8) , 5075-5093
Engineering of Dual-Functionalized Intranasal Nanovesicles Embedded with Thymoquinone for Targeted Modulation of the PI3K/AKT Pathway in Glioblastoma Therapy
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor, known for its invasiveness, therapy resistance, and the challenge posed by the blood-brain barrier (BBB). This study presents a novel, dual-functionalized nanovesicular system for intranasal delivery of thymoquinone (TH), encapsulated in PEGylated chitosan-coated NVs and conjugated with lactoferrin (Lf). This formulation (TH-Lf-PEG-CS-NVs) was optimized using a central composite design and exhibited high entrapment efficiency (96.28 ± 0.65%), a particle size of 129.82 ± 0.53 nm, and coating efficiency of 91.72 ± 0.22%. In vitro and ex vivo studies demonstrated superior cellular uptake (84.01 ± 3.78%) and a ∼3.16-fold increase in permeability (Papp: 0.57 ± 0.072 μg/cm2/min) compared to free TH. Mechanistic assays confirmed modulation of the PI3K/AKT pathway, with reduced Bcl-2 (56.91 ± 2.98%), COX-2 (31.22 ± 2.19%), and increased caspase-3 (75.9 ± 3.01%) expression. In vivo pharmacokinetics revealed a peak cerebrospinal fluid concentration (Cmax) of 51.72 ± 1.22 μg/mL at 24 h and sustained release for 36 h. Histopathological evaluations affirmed safety and biocompatibility. This multifunctional nanocarrier facilitates targeted delivery, effective BBB penetration, and prolonged cerebral retention, offering a noninvasive, efficient strategy for GBM treatment. The findings support its potential as a translational therapeutic platform for central nervous system malignancies.
- Open Access
- 20 December 2024
- Published by Elsevier in Pharmacological Research - Modern Chinese Medicine
- Vol. 14
In-vitro and in-vivo assessment of cytotoxic potential of β-1,3 beta-glucan comprising Lentinan against glioblastoma multiforme
- 20 December 2024
- Published by Elsevier in Pharmacological Research - Modern Chinese Medicine
- Vol. 14
Open AccessIn-vitro and in-vivo assessment of cytotoxic potential of β-1,3 beta-glucan comprising Lentinan against glioblastoma multiforme
- Open Access
- 7 September 2024
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 139-145
ANALYTICAL QUANTIFICATION OF BOSUTINIB IN NANOCARRIER USING UV AND HPLC: METHOD DEVELOPMENT AND VALIDATION
Objective: Bosutinib, a potent tyrosine kinase inhibitor, holds significant promise in cancer therapy, particularly in Breast Cancer treatment. This study focuses on the analytical quantification of Bosutinib in Nanocarriers (BNCs) essential for quantification in terms of targeted delivery. Methods: A comprehensive method development and validation process was undertaken utilizing UV-visible spectroscopy and High-Performance Liquid Chromatography (HPLC). Preformulation studies confirmed the purity and physicochemical properties of bosutinib. UV-visible spectroscopy established a calibration curve for bosutinib and BNCs, with precision, accuracy, Limits of Detection (LOD), and Limits of Quantification (LOQ) determined. HPLC analysis further validated bosutinib quantification, ensuring the robustness and reliability of the analytical method. Results: Bosutinib and BNCs were evaluated using UV-visible spectroscopy, revealing λ max at 263 nm and 277 nm, respectively, showing a strong correlation with the regression coefficient (R2) being 0.9969 and 0.9994, respectively. The precision (intra-day and inter-day) data shows strong reproducibility with a Percentage Relative Standard Deviation (%RSD) of less than 1.5%. Completely distinguished sharp peaks of bosutinib and BNCs were developed using HPLC under ambient settings; 3.974±0.006 and 3.083±0.004 was the Resolution Time (Rt) at which bosutinib and BNCs were discovered, respectively. The Theoretical Plate (TP) values of 5179±93 and 2598±85 and the Tailing Factor (TF) of1.00±0.002 and 1.10±0.004 were both within the predetermined bounds. Conclusion: The developed UV and HPLC methods offer accurate and reliable quantification of bosutinib in a nanocarrier, essential for optimizing drug delivery strategies and therapeutic outcomes in cancer treatment. This analytical approach contributes to advancing pharmaceutical research in precision medicine and targeted drug delivery systems.
- 7 September 2024
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 139-145
Open AccessANALYTICAL QUANTIFICATION OF BOSUTINIB IN NANOCARRIER USING UV AND HPLC: METHOD DEVELOPMENT AND VALIDATION
Objective: Bosutinib, a potent tyrosine kinase inhibitor, holds significant promise in cancer therapy, particularly in Breast Cancer treatment. This study focuses on the analytical quantification of Bosutinib in Nanocarriers (BNCs) essential for quantification in terms of targeted delivery. Methods: A comprehensive method development and validation process was undertaken utilizing UV-visible spectroscopy and High-Performance Liquid Chromatography (HPLC). Preformulation studies confirmed the purity and physicochemical properties of bosutinib. UV-visible spectroscopy established a calibration curve for bosutinib and BNCs, with precision, accuracy, Limits of Detection (LOD), and Limits of Quantification (LOQ) determined. HPLC analysis further validated bosutinib quantification, ensuring the robustness and reliability of the analytical method. Results: Bosutinib and BNCs were evaluated using UV-visible spectroscopy, revealing λ max at 263 nm and 277 nm, respectively, showing a strong correlation with the regression coefficient (R2) being 0.9969 and 0.9994, respectively. The precision (intra-day and inter-day) data shows strong reproducibility with a Percentage Relative Standard Deviation (%RSD) of less than 1.5%. Completely distinguished sharp peaks of bosutinib and BNCs were developed using HPLC under ambient settings; 3.974±0.006 and 3.083±0.004 was the Resolution Time (Rt) at which bosutinib and BNCs were discovered, respectively. The Theoretical Plate (TP) values of 5179±93 and 2598±85 and the Tailing Factor (TF) of1.00±0.002 and 1.10±0.004 were both within the predetermined bounds. Conclusion: The developed UV and HPLC methods offer accurate and reliable quantification of bosutinib in a nanocarrier, essential for optimizing drug delivery strategies and therapeutic outcomes in cancer treatment. This analytical approach contributes to advancing pharmaceutical research in precision medicine and targeted drug delivery systems.